NuCana appoints Professor Chris McGuigan as Chief Scientific Officer

McGuigan was the original inventor of the ProTide technology used in the NuCana Aceleran product

NuCana, a clinical stage biopharmaceutical company based in Edinburgh, Scotland, which is using proprietary ProTide technology to develop a portfolio of novel anti-cancer drugs, has appointed Professor Chris McGuigan as Chief Scientific Officer.

McGuigan was the original inventor of the ProTide technology. He is currently Professor of Medicinal Chemistry at the Cardiff School of Pharmacy and Pharmaceutical Sciences in Wales. He is also Chair of the Life Sciences Hub Wales, having been appointed by the Welsh Government's Economy Minister in 2014.

McGuigan has more than 30 years' experience in phosphoramidate (ProTide) chemistry and has generated more than 4,500 new chemical entities. In 2001 he was the co-recipient of the Descartes Prize for outstanding scientific achievement in the field of ProTide chemistry. He has an internationally renowned reputation for his academic work and has published more than 225 scientific papers. In addition, he has worked closely with the life sciences industry to apply his skills to develop a series of new medicines.

NuCana's first ProTide, Acelarin, is entering Phase III studies. The recently completed Phase I/II study showed the potential of ProTides to define 'a new era in cancer treatment', according to McGuigan.

You may also like

Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Manufacturing

Anton Paar expands Litesizer DIA Series with new models

Introducing affordable and advanced solutions for particle analysis
Manufacturing

Triple your efficiency with the new DrySyn Vortex

Boost productivity with temperature-controlled parallel reactions
Subscribe now